{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000780","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.841768+00:00","generated_at":"2026-05-16T11:04:25.444870+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunocore reports prelim cash $864M, sets 2026 priorities including TEBE-AM enrollment completion in 1H 2026","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities ~$864M as of Dec 31, 2025.","TEBE-AM Phase 3 cutaneous melanoma trial enrollment completion expected 1H 2026; topline data as early as 2H 2026.","Phase 1/2 PRAME data expected 2H 2026: brenetafusp combos in ovarian and NSCLC, initial IMC-P115C data.","First patient in Phase 1 type 1 diabetes trial (IMC-S118AI) expected 1H 2026; autoimmune trial app for atopic dermatitis in 2H 2026.","KIMMTRAK enters 5th year post-approval; expects moderate revenue growth driven by community and global penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000780","json":"https://secwatch.observer/filing/0001140361-26-000780.json","markdown":"https://secwatch.observer/filing/0001140361-26-000780.md","text":"https://secwatch.observer/filing/0001140361-26-000780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/0001140361-26-000780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036126000780/ef20062561_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:04:25.444870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}